BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
And whether we continue the checkpoint inhibitor or not, there is data in kidney cancer where there is no benefit to continuing a checkpoint inhibitor once a patient has progressed on it. But most of it has been done in the metastatic setting, although the most recent data with Tivolumab was done a little bit earlier.
0
💬
0
Comments
Log in to comment.
There are no comments yet.